ClinicalTrials.gg
CompletedNCT00494442ICEBERG 2Updated Aug 1, 2018Results posted

Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer

A Phase 2 interventional study of KU-0059436 (AZD2281)(PARP inhibitor) and KU-0059436 (AZD2281)(PARP inhibitor) in Ovarian Neoplasm, sponsored by AstraZeneca. Completed at 11 sites in 5 countries. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2018-08-01.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
58
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 69 studies testing olaparib in Ovarian Neoplasms — 13 open to participants now, 26 under way, 9 of them phase 3. olaparib · Ovarian Neoplasms.

Enrollment
40th of 69
58 · median 96
Started
2007
with 1 other
Phase 2
32 of 69
7 open now
Registered
1st of 69
by date
Lead sponsor
21 of 69
AstraZeneca

Among the 69 studies testing olaparib in Ovarian Neoplasms, this one is the 40th largest by enrollment, is one of 2 that started in 2007, is one of 32 in phase 2, and was the 1st registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

13 of the 69 studies testing olaparib in Ovarian Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About olaparib

olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 130 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing olaparib in Ovarian Neoplasms, or all of them as a file.
02

Study summary

The purpose of the study is to see if the drug KU 0059436 is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and for whom no curative therapeutic option exists.

03

Conditions studied

  • Ovarian Neoplasm

Keywords

  • Advanced ovarian cancer
  • Poly(ADP ribose) polymerases
  • KU-0059436
  • AZD2281
  • BRCA1 protein
  • BRCA2 protein
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Advanced ovarian cancer with positive BRCA1 or BRCA2 status
  • Failed at least one prior chemotherapy
  • In investigators opinion, no curative standard therapy exists

Exclusion criteria

Exclusion Criteria:

  • Less than 28 days since last treatment used to treat the disease
  • Considered a poor medical risk due to a serious uncontrolled disorder
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    KU-0059436 (AZD2281) 100 mg BID

    Drug: KU-0059436 (AZD2281)(PARP inhibitor)

  • Experimental
    KU-0059436 (AZD2281) 400 mg BID

    Drug: KU-0059436 (AZD2281)(PARP inhibitor)

Interventions

06

What researchers measure

Primary outcomes

  1. Confirmed Objective Tumour Response (According to Response Evaluation Criteria In Solid Tumors (RECIST)

    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT/MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease from baseline in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: Baseline, every 8 also at study termination or initiation of confounding anti-cancer therapy.

Secondary outcomes

  1. Clinical Benefit (CB)

    Clinical Benefit (CB) is defined as the percentage of patients with a RECIST tumour response of confirmed complete response, partial response or stable disease for ≥8 weeks)

    Time frame: End of study

  2. Duration of Response

    Duration of response to olaparib

    Time frame: End of study

  3. Best Percentage Change in Tumour Size

    The best % change (reduction) from baseline in tumour size (defined as the sum of the longest diameters as measured among all target lesions).

    Time frame: End of study

  4. Progression-Free Survival (PFS)

    Progression-Free Survival (PFS) is defined as the time from first dose to the earlier date of radiologic progression (as per RECIST criteria) or death by any cause in the absence of objective progression.

    Time frame: End of study

07

Results

Posted Jan 26, 2015

Participant flow

The first patient was enrolled on June 11, 2007 and efficacy and safety data were collected up to the data cut-off of March 17, 2009. Patients were enrolled at 12 centres in 5 countries: Australia, Germany, Spain, Sweden and the USA.

Participant flow — Overall Study
MilestoneOlaparib 100 mg bdOlaparib 400 mg bd
Started2433
Completed717
Not completed1716
Withdrew: Death11
Withdrew: Lack of efficacy1610
Withdrew: Adverse event02
Withdrew: Physician decision01
Withdrew: Non-compliance01
Withdrew: Intercurrent illness01

Outcome measures

PrimaryConfirmed Objective Tumour Response (According to Response Evaluation Criteria In Solid Tumors (RECIST)

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT/MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease from baseline in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
Baseline, every 8 also at study termination or initiation of confounding anti-cancer therapy.
Reported as:
Number · Participants
Confirmed Objective Tumour Response (According to Response Evaluation Criteria In Solid Tumors (RECIST)
ParticipantsOlaparib 100 mg bdOlaparib 400 mg bd
PP Analysis Set311
ITT Analysis Set311
SecondaryClinical Benefit (CB)

Clinical Benefit (CB) is defined as the percentage of patients with a RECIST tumour response of confirmed complete response, partial response or stable disease for ≥8 weeks)

Time frame:
End of study
Reported as:
Number · Percentage of participants
Clinical Benefit (CB)
Percentage of participantsOlaparib 100 mg bdOlaparib 400 mg bd
Clinical Benefit (CB)45.5 (26.9 to 65.3)71.0 (53.4 to 83.9)
SecondaryDuration of Response

Duration of response to olaparib

Time frame:
End of study
Reported as:
Median · Days
Duration of Response
DaysOlaparib 100 mg bdOlaparib 400 mg bd
Duration of Response242 (169 to 288)301 (126 to 506)
SecondaryBest Percentage Change in Tumour Size

The best % change (reduction) from baseline in tumour size (defined as the sum of the longest diameters as measured among all target lesions).

Time frame:
End of study
Reported as:
Median · Percent change
Best Percentage Change in Tumour Size
Percent changeOlaparib 100 mg bdOlaparib 400 mg bd
Best Percentage Change in Tumour Size-5.1 (-85.7 to 66.1)-25.8 (-100.0 to 150.0)
SecondaryProgression-Free Survival (PFS)

Progression-Free Survival (PFS) is defined as the time from first dose to the earlier date of radiologic progression (as per RECIST criteria) or death by any cause in the absence of objective progression.

Time frame:
End of study
Reported as:
Median · Days
Progression-Free Survival (PFS)
DaysOlaparib 100 mg bdOlaparib 400 mg bd
Progression-Free Survival (PFS)62.5 (56 to 113)226 (105 to 338)

Adverse events

Collected over From baseline, every visit until 30 days after last dose.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Olaparib 100 mg bd10/24 (41.7%)7/24 (29.2%)23/24 (95.8%)
Olaparib 400 mg bd11/33 (33.3%)12/33 (36.4%)33/33 (100%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventOlaparib 100 mg bdOlaparib 400 mg bd
Intestinal ObstructionGastrointestinal disorders0/242/33
NauseaGastrointestinal disorders1/242/33
VomitingGastrointestinal disorders1/242/33
NeutropeniaBlood and lymphatic system disorders1/241/33
Cardiac Failure CongestiveCardiac disorders1/240/33
Abdominal PainGastrointestinal disorders1/240/33
Large Intestinal ObstructionGastrointestinal disorders1/241/33
Blood Pressure IncreasedInjury, poisoning and procedural complications1/240/33
HyponatraemiaMetabolism and nutrition disorders1/240/33
EncephalopathyNervous system disorders1/240/33
Most frequent other events
Showing 10 of 66
Most frequent other events
EventOlaparib 100 mg bdOlaparib 400 mg bd
NauseaGastrointestinal disorders15/2421/33
FatigueGeneral disorders13/2417/33
DiarrhoeaGastrointestinal disorders7/2412/33
VomitingGastrointestinal disorders6/2411/33
Abdominal PainGastrointestinal disorders4/249/33
ConstipationGastrointestinal disorders6/244/33
AnaemiaBlood and lymphatic system disorders3/247/33
HeadacheNervous system disorders4/247/33
Urinary Tract InfectionInfections and infestations5/242/33
RashSkin and subcutaneous tissue disorders5/245/33

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Olaparib 100 mg bdOlaparib 400 mg bdTotal
Mean55.6 ± 8.0256.8 ± 10.4956 ± 9
Sex: Female, Male
Sex: Female, Male(Participants)Olaparib 100 mg bdOlaparib 400 mg bdTotal
Female243357
Male000
BRCA mutation
BRCA mutation(Participants)Olaparib 100 mg bdOlaparib 400 mg bdTotal
BRCA1192140
BRCA251217
08

Study locations

11 sites
  • Research Site
    Los Angeles, California 90048, United States
  • Research Site
    San Francisco, California 94115, United States
  • Research Site
    Boston, Massachusetts 02115, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Melbourne, Parkville, VIC 3050, Australia
  • Research Site
    Melbourne, 3000, Australia
  • Research Site
    Randwick, 2031, Australia
  • Research Site
    Köln, 50931, Germany
  • Research Site
    Hospitalet deLlobregat, 08907, Spain
  • Research Site
    Lund, S-221 85, Sweden
09

References and documents

Publications

  • Matulonis UA, Penson RT, Domchek SM, Kaufman B, Shapira-Frommer R, Audeh MW, Kaye S, Molife LR, Gelmon KA, Robertson JD, Mann H, Ho TW, Coleman RL. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety. Ann Oncol. 2016 Jun;27(6):1013-1019. doi: 10.1093/annonc/mdw133. Epub 2016 Mar 8. PubMed 26961146 ↗
  • Ang JE, Gourley C, Powell CB, High H, Shapira-Frommer R, Castonguay V, De Greve J, Atkinson T, Yap TA, Sandhu S, Banerjee S, Chen LM, Friedlander ML, Kaufman B, Oza AM, Matulonis U, Barber LJ, Kozarewa I, Fenwick K, Assiotis I, Campbell J, Chen L, de Bono JS, Gore ME, Lord CJ, Ashworth A, Kaye SB. Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. Clin Cancer Res. 2013 Oct 1;19(19):5485-93. doi: 10.1158/1078-0432.CCR-13-1262. Epub 2013 Aug 6. PubMed 23922302 ↗
  • Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010 Jul 24;376(9737):245-51. doi: 10.1016/S0140-6736(10)60893-8. Epub 2010 Jul 6. PubMed 20609468 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2007 to primary completion in Mar 2009, 21 months.

Results were first posted in Jan 2015, 5 years 10 months after primary completion. A results delay was requested in Sep 2013.

Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's 21 months is below that.

Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2007
First posted
Jun 29, 2007
StartActual
Jun 11, 2007
Primary completionActual
Mar 17, 2009
CompletionActual
Jul 20, 2017
Results delay requested
Sep 17, 2013
Results first posted
Jan 26, 2015
Last update
Aug 1, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00494442
Lead sponsor
AstraZeneca
Collaborators
KuDOS Pharmaceuticals Limited
Responsible party
Sponsor
First posted
Jun 29, 2007
Start date
Jun 11, 2007
Primary completion
Mar 17, 2009
Completion
Jul 20, 2017
Results posted
Jan 26, 2015
Last update
Aug 1, 2018

Study contacts

James Carmichael, BSc MBChB MD FRCP
study director · KuDOS Pharmaceuticals Limited
Andrew Tutt, PhD MRCP FRCR
principal investigator · Guy's and St Thomas's NHS Foundation Trust, London, UK

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion